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ĂAbstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53S30participated in either dietary maintenance, knee exercise or a control
group for 1 year. The cartilage loss was not associated with changes in
symptoms.Trial registration: {NCT00655941}ANCOVA results for changes in weight, BMI and cartilage volumes (mm3) and average symptoms (KOOS)
Group C Group D Group E ANCOVA
Mean 95% CI Mean 95% CI Mean 95% CI P-value
Weight, kg -9.8 -11.7 to -7.8 -12.8 -14.7 to -11.0 -8.0 -9.9 to -6.1 0.0018
BMI -3.5 -4.2 to -2.8 -4.6 -5.3 to -4.0 -2.9 -3.6 to -2.2 0.0023
Cartilage Volume (mm3)
Total knee -1219 -1378 to -1061 -1119 -1273 to -965 -1112 -1275 to -949 0.5770
Lateral Femoral -251 -284 to -219 -227 -259 to -196 -236 -270 to -203 0.5755
Medial Femoral -319 -363 to -275 -269 -311 to -226 -285 -330 to -340 0.2651
Patellar -214 -261 to -167 -202 -247 to -156 -167 -215 to -119 0.3595
Lateral Tibial -265 -331 to -199 -246 -309 to -182 -279 -347 to -211 0.7745
Medial Tibial -172 -238 to -107 -173 -237 to -110 -146 -214 to 78 0.8099
Average Symptoms (KOOS) 8.3 4.6 to 11.9 9.0 5.5 to 12.6 7.8 4.1 to 11.4 0.884340
BLOCKING COLLAGENOLYSIS PREVENTS AGGRECAN LOSS MORE
EFFECTIVELY THAN BLOCKING AGGRECANOLYSIS IN THE
AGGRECAN INTERGLOBULAR DOMAIN, IN VITRO AND IN VIVO
S.J. Gauci 1, C.B. Little 2, A.J. Fosang 3. 1Murdoch Childrens Res. Inst., VIC,
Australia; 2Raymond Purves Bone & Joint Res. Labs, Univ. of Sydney,
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Purpose: We have compared knockin mice with aggrecan and type II
collagenresistant toaggrecanases, collagenases,orboth familiesofenzymes,
to identify the most important proteolytic driver for cartilage erosion.
Speciﬁcally, the cleavage site in the aggrecan interglobular domain (IGD) of
Jaffa is changed from E373Y374ALG to E373Y374NVY and the collagenase
cleavage site in the a1(II) chain of Bailey is changed from PQG775Y776LAG to
PPG775Y776MPG.The Jaffamutationdoesnot inﬂuenceaggrecanasecleavage
at sites in the chondroitin sulphate-rich region of aggrecan. In contrast,
blocking cleavage at the primary collagenase cleavage site prevents
secondaryand subsequent cleavage events inBailey type II collagen. Juniper
mice are resistant to both aggrecanases and collagenases
Methods: Aggrecan released into the medium from Wildtype, Bailey,
Jaffa and Juniper femoral head cartilage explants (n¼ 5-6 per genotype),
treated for 3 days  IL-1, was measured by the DMMB assay. Cartilage
used in the explant experiments was homozygous for all genotypes. We
used the DMM surgical model of OA to compare tibial cartilage erosion
in Wildtype, Bailey, Jaffa and Juniper mice at 8-weeks post-surgery.
Morphological joint abnormalities in homozygous Bailey precluded
their use in arthritis studies. Accordingly, the in vivo comparisons were
made between heterozygous Bailey, homozygous Jaffa and Juniper mice
that were heterozygous for the Baileymutation and homozygous for the
Jaffa mutation. Sagittal sections collected at 40mm intervals through the
medial compartment of the knee were scored for aggrecan loss and
cartilage erosion by two independent scorers blinded to the genotype.
The data were analysed by the Mann-Whitney U-test
Results: Aggrecan loss from explants treated with IL-1a was signiﬁ-
cantly reduced in all mutant genotypes compared with Wildtype.
Juniper explants lost the least amount of aggrecan. The hierarchy of
aggrecan loss was Wildtype > Jaffa > Bailey > Juniper samples.
Aggrecan loss from explants treated with retinoic acid was also signif-
icantly reduced in all mutant genotypes compared with wildtype; again
Juniper explants lost the least amount of aggrecan. However, withretinoic acid treatment, the hierarchy of aggrecan loss was Wildtype >
Bailey > Jaffa > Juniper samples. We measured aggrecan loss and
cartilage erosion 8-weeks after DMM surgery and as predicted, found
that both aggrecan loss and tibial cartilage erosion were signiﬁcantly
reduced in Juniper comparedwithWildtype. For aggrecan loss, whereas
there was no protection in Jaffa compared with Wildtype at 8 weeks,
the aggrecan loss from Bailey was signiﬁcantly less than for Wildtype.
For cartilage erosion, both Bailey and Jaffa were protected compared
with Wildtype at 8 weeks. Similarly, Juniper was better protected
against cartilage erosion than either Jaffa or Bailey
Conclusions: Mutations that partially block collagenolysis (heterozy-
gous Bailey) and aggrecanolysis (homozygous Jaffa for the IGD site only)
protect against cartilage erosion in experimental OA. Furthermore,
protecting collagen II against collagenase attack is equal to, or better
than, protecting aggrecan against IGD aggrecanase cleavage, in terms of
cartilage erosion and aggrecan loss respectively (see Figure)41
S100A8 AND S100A9 ACT AS ‘PRIMERS’ OF A CATABOLIC RESPONSE
IN CHONDROCYTES BUT ADDITIONAL SIGNALS ARE REQUIRED TO
ACTIVATE CARTILAGE DEGRADATION
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Purpose: Calcium binding proteins S100A8 and S100A9 are increased in
cartilage in acute and chronic inﬂammatory arthritis; however their
role in osteoarthritis (OA) is less clear. Chondrocyte S100A8 and S100A9
mRNA are increased during the onset of surgically induced murine OA,
but both are signiﬁcantly downregulated as OA progresses. Interest-
ingly, recent studies have shown that cartilage in S100A9-/- deﬁcient
mice is protected from degradation in joint instability accompanied by
signiﬁcant synovitis (collagenase-induced-) but not surgically-induced-
OA. Whether this is due tomore persistent expression of S100A8 and/or
A9 or release of additional co-factors from the inﬂamed synovium in the
collagenase model is unclear. S100A8 and S100A9, but not the hetero-
dimer (S100A8/A9) rapidly induceMMP and ADAMTSmRNA expression
in chondrocytes, but whether this leads to actual cartilage matrix
breakdown has not been resolved. The aim of this study was to deter-
mine whether S100A8 or S100A9 alone or in combination with IL-1 can
activate MMPs and aggrecanases with resultant chondrolysis and
whether this is time-dependent.
Methods: Normal ovine articular cartilage explants were cultured for 1,
2, 4, 7 or 14 days in serum-free media  10-7M human S100A8, S100A9
or S100A8/A9, with or without 10ng/ml IL-1a (n¼6/treatment). Gene
expression of S100A8, S100A9, key cartilage proteins, metal-
loproteinases and their inhibitors was measured using qRT-PCR.
Collagen and aggrecan release were measured as hydroxyproline and
glycosaminoglycan respectively. Media MMP-2 and MMP-9 activity
were evaluated by gelatin zymography and MMP-13 using a ﬂuoro-
metric assay.
Results: S100A8 and S100A9 alone signiﬁcantly (p<0.05) up-regulated
MMP1, MMP3, S100A9, ADAMTS5 and MMP13 mRNA throughout the
